Maxim analyst Allen Klee raised the firm’s price target on CareCloud to $12 from $11 and keeps a Buy rating on the shares. The company’s investor day presentation highlights its transformation to a full service provider with multiple growth opportunities, the analyst tells investors in a research note. Klee adds that he expects CareCloud’s new digital health solutions to be the key driver to accelerate organic growth to the high single-digit range from low single-digits starting in 2024.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MTBC:
- CareCloud Hosts Inaugural Analyst and Investor Day, Emphasizes Goal to Help Providers Embrace the Next Generation of Healthcare
- CareCloud to host virtual analyst and investor day
- CareCloud to participate in a webinar with Ladenburg Thalmann
- CareCloud’s medSR Division Chosen by Russell Medical Center to Implement New Electronic Health Record Platform
- CareCloud’s medSR division chosen by Russell Medical Center
